Domain Therapeutics achieves two discovery milestones in collaboration with Boehringer Ingelheim
The two companies pursue the collaboration on the ongoing projects with the final objective to nominate preclinical candidates for…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Boehringer Ingelheim
Lupin and Boehringer Ingelheim partner to develop and commercialise novel oncology drug to treat…
The partnership aims to develop Lupin’s lead MEK inhibitor compound in combination with one of Boehringer Ingelheim’s innovative…
Lifesciences sector posts 52 deals worth $1.6 bn in July 2019
Deal value in healthcare industry declines in July 2019
DRL receives US FDA approval
The company has received the approval for Aspirin and Extended-Release dipyridamole capsules in the US Market
Dr Reddy’s Labs, …
Lupin in agreement with Boehringer Ingelheim
Lupin to market Linagliptin for Boehringer Ingelheim under the brand name Ondero and Ondero Met in India
Lupin and Boehringer…